DK2970383T3 - Fremgangsmåde til behandling af fibrose - Google Patents
Fremgangsmåde til behandling af fibrose Download PDFInfo
- Publication number
- DK2970383T3 DK2970383T3 DK14762435.7T DK14762435T DK2970383T3 DK 2970383 T3 DK2970383 T3 DK 2970383T3 DK 14762435 T DK14762435 T DK 14762435T DK 2970383 T3 DK2970383 T3 DK 2970383T3
- Authority
- DK
- Denmark
- Prior art keywords
- treating fibrosis
- fibrosis
- treating
- Prior art date
Links
- 206010016654 Fibrosis Diseases 0.000 title 1
- 230000004761 fibrosis Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361800117P | 2013-03-15 | 2013-03-15 | |
| PCT/US2014/030147 WO2014145389A1 (en) | 2013-03-15 | 2014-03-17 | Inhibition of pulmonary fibrosis with nutlin-3a and peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2970383T3 true DK2970383T3 (da) | 2021-07-05 |
Family
ID=51537978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14762435.7T DK2970383T3 (da) | 2013-03-15 | 2014-03-17 | Fremgangsmåde til behandling af fibrose |
Country Status (12)
| Country | Link |
|---|---|
| US (7) | US9630990B2 (da) |
| EP (2) | EP3929207A1 (da) |
| JP (4) | JP6603207B2 (da) |
| KR (3) | KR102588702B1 (da) |
| CN (3) | CN117679487A (da) |
| AU (3) | AU2014233055B2 (da) |
| CA (1) | CA2904870C (da) |
| DK (1) | DK2970383T3 (da) |
| ES (1) | ES2875853T3 (da) |
| HK (1) | HK1218924A1 (da) |
| PT (1) | PT2970383T (da) |
| WO (1) | WO2014145389A1 (da) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2412800A1 (en) | 2010-07-29 | 2012-02-01 | Koninklijke Nederlandse Akademie van Wetenschappen | Liver organoid, uses thereof and culture method for obtaining them |
| EP2393917B1 (en) | 2009-02-03 | 2016-04-06 | Koninklijke Nederlandse Akademie van Wetenschappen | Culture medium for epithelial stem cells and organoids comprising said stem cells. |
| KR102588702B1 (ko) * | 2013-03-15 | 2023-10-16 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 누트린-3a 및 펩티드에 의한 폐 섬유증의 저해 |
| AU2015211021B2 (en) | 2014-01-28 | 2020-07-02 | Buck Institute For Research On Aging | Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders |
| US10328058B2 (en) | 2014-01-28 | 2019-06-25 | Mayo Foundation For Medical Education And Research | Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques |
| US20170216286A1 (en) | 2014-01-28 | 2017-08-03 | Mayo Foundation For Medical Education And Research | Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid |
| US10597633B2 (en) | 2014-05-16 | 2020-03-24 | Koninklijke Nederlandse Akademie Van Wetenschappen | Culture method for organoids |
| GB201421092D0 (en) | 2014-11-27 | 2015-01-14 | Koninklijke Nederlandse Akademie Van Wetenschappen | Culture medium |
| GB201421094D0 (en) | 2014-11-27 | 2015-01-14 | Koninklijke Nederlandse Akademie Van Wetenschappen | Culture medium |
| CA2977519A1 (en) * | 2015-02-27 | 2016-09-01 | Board Of Regents, The University Of Texas System | Nebulized cav-1 polypeptide therapeutics and uses thereof |
| GB201603569D0 (en) | 2016-03-01 | 2016-04-13 | Koninklijke Nederlandse Akademie Van Wetenschappen | Improved differentiation method |
| KR102082285B1 (ko) * | 2017-04-13 | 2020-02-28 | 충남대학교산학협력단 | 세포내 결핵균 제어를 위한 Nutlin-3α (뉴트린-3α) 및 p53 발현 조절 조성물 또는 방법 |
| WO2018190680A1 (ko) * | 2017-04-13 | 2018-10-18 | 충남대학교산학협력단 | 세포내 결핵균 제어를 위한 뉴트린-3α 및 피53 발현 조절 조성물 또는 방법 |
| CN107987128B (zh) * | 2017-11-17 | 2019-06-11 | 广东医科大学 | 一种功能多肽及其在制备防治肺纤维化药物中的应用 |
| WO2020014652A1 (en) * | 2018-07-13 | 2020-01-16 | New York University | Peptoid-peptide macrocycles, pharmaceutical compositions and methods of using the same |
| JP7496826B2 (ja) * | 2018-09-10 | 2024-06-07 | ラング セラピューティクス，エルエルシー | Ｃａｖ－１タンパク質の修飾ペプチドフラグメント及び線維症の治療におけるその使用 |
| CN112996530A (zh) * | 2018-09-10 | 2021-06-18 | 得克萨斯州大学系统董事会 | 小窝蛋白-1肽的干粉制剂及其使用方法 |
| CN109010798A (zh) * | 2018-09-17 | 2018-12-18 | 中山大学中山眼科中心 | 一种多肽的新用途 |
| JP2023509666A (ja) * | 2019-12-31 | 2023-03-09 | シァメン・ユニヴァーシティ | 分子の細胞内送達用の多量体化送達システム |
| WO2022217037A1 (en) * | 2021-04-09 | 2022-10-13 | Board Of Regents, The University Of Texas System | Compositions and methods for treatment of chronic lung diseases |
| CN116789751B (zh) * | 2023-08-22 | 2023-11-17 | 中国农业大学 | 预防和/或治疗纤维化疾病的多肽及其应用 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3691016A (en) | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes |
| CA1023287A (en) | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Process for the preparation of carrier-bound proteins |
| US4021387A (en) | 1975-11-19 | 1977-05-03 | President And Fellows Of Harvard College | Eosinophilotactic tetrapeptides |
| US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
| US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
| CA1093991A (en) | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Enzyme immobilization with pullulan gel |
| US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
| US4816449A (en) | 1984-08-09 | 1989-03-28 | Immunetech Pharmaceuticals | Immunotherapeutic anti-inflammatory peptide agents |
| US4613676A (en) * | 1983-11-23 | 1986-09-23 | Ciba-Geigy Corporation | Substituted 5-amino-4-hydroxyvaleryl derivatives |
| ZA846192B (en) | 1984-08-09 | 1986-03-26 | Merck Patent Gmbh | Immunotherapeutic polypeptide agents |
| US5728680A (en) | 1987-12-30 | 1998-03-17 | Cytoven J.V. | Methods for normalizing numbers of lymphocytes |
| DK53291D0 (da) * | 1991-03-25 | 1991-03-25 | Carlbiotech Ltd As | Smaa peptider og peptidrelaterede stoffer samt farmaceutiske praeparater indeholdende saadanne forbindelser |
| CA2150371C (en) * | 1992-12-11 | 2002-09-17 | Dov Borovsky | Materials and methods for control of pests |
| US5559209A (en) * | 1993-02-18 | 1996-09-24 | The General Hospital Corporation | Regulator regions of G proteins |
| US6126939A (en) | 1996-09-03 | 2000-10-03 | Yeda Research And Development Co. Ltd. | Anti-inflammatory dipeptide and pharmaceutical composition thereof |
| US6017735A (en) | 1997-01-23 | 2000-01-25 | Marie Curie Cancer Care | Materials and methods for intracellular transport and their uses |
| US20030113271A1 (en) | 1997-01-29 | 2003-06-19 | University Technology Corporation | Formulations for pulmonary delivery |
| EP1076091A1 (en) | 1999-08-09 | 2001-02-14 | Universite Catholique De Louvain | Medicament for the prevention and/or the treatment of ischemic heart and peripheral vascular diseases, tumour and wounds |
| US20020077283A1 (en) | 2000-09-08 | 2002-06-20 | Sessa William C. | Caveolin peptides and their use as therapeutics |
| EP1353676A4 (en) | 2000-12-29 | 2006-05-31 | Alteon Inc | METHOD FOR THE TREATMENT OF FIBROUS OR OTHER INDICATIONS |
| GB0119852D0 (en) | 2001-08-15 | 2001-10-10 | Univ York | Baculovirus |
| RU2305095C2 (ru) | 2001-12-18 | 2007-08-27 | Ф.Хоффманн-Ля Рош Аг | Цис-2,4,5-трифенилимидазолины и фармацевтическая композиция на их основе |
| EP1734938B1 (en) | 2004-03-26 | 2012-06-20 | Universita' Degli Studi Di Parma | Insulin highly respirable microparticles |
| CA2568428C (en) * | 2004-05-25 | 2020-12-29 | Attenuon, Llc | Ligands binding the complex of urokinase-type plasminogen activator (upa) and its receptor (upar) that inhibit downstream upar interactions: identification and use in diagnosis or therapy |
| US7893278B2 (en) | 2004-06-17 | 2011-02-22 | Hoffman-La Roche Inc. | CIS-imidazolines |
| TWI299993B (en) | 2005-12-15 | 2008-08-21 | Dev Center Biotechnology | Aqueous inhalation pharmaceutical composition |
| US8058227B2 (en) * | 2006-10-03 | 2011-11-15 | Medical University Of South Carolina | Method of treating fibrosis in a subject in need thereof comprising administering a composition comprising a CSD |
| EP2074142A4 (en) | 2006-10-19 | 2010-10-27 | Angiochem Inc | COMPOUNDS FOR STIMULATING THE FUNCTION OF P-GLYCOPROTEIN AND APPLICATIONS THEREOF |
| EP2220115A2 (en) | 2007-12-13 | 2010-08-25 | Glaxo Group Limited | Polypeptides, antibody variable domains & antagonists |
| KR101593708B1 (ko) * | 2007-12-21 | 2016-02-12 | 피브로테크 세라퓨틱 피티와이 엘티디 | 항섬유증 제제의 할로겐화 유사체 |
| US8697840B2 (en) | 2008-03-05 | 2014-04-15 | Board Of Regents, The University Of Texas System | Peptide inhibition of lung epithelial apoptosis and pulmonary fibrosis |
| US20100129375A1 (en) | 2008-09-10 | 2010-05-27 | Genentech, Inc. | Methods for inhibiting ocular angiogenesis |
| GB2466121B (en) | 2008-12-15 | 2010-12-08 | Amira Pharmaceuticals Inc | Antagonists of lysophosphatidic acid receptors |
| PL3501499T3 (pl) | 2010-02-11 | 2023-01-09 | Ablynx Nv | Sposoby i kompozycje do wytwarzania aerozoli |
| EP2635686B1 (en) | 2010-11-05 | 2018-03-28 | The Regents of The University of California | Neuronal specific targeting of caveolin expression to restore synaptic signaling and improve cognitive function in the neurodegenerative brain and motor function in spinal cord |
| US20150141340A1 (en) * | 2012-06-04 | 2015-05-21 | Yale University | Method of treating and preventing ocular angiogenesis |
| US10441536B2 (en) | 2013-03-13 | 2019-10-15 | Actavis Group Ptc Ehf | Micronized colistimethane sodium pharmaceutical compositions |
| KR102588702B1 (ko) | 2013-03-15 | 2023-10-16 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 누트린-3a 및 펩티드에 의한 폐 섬유증의 저해 |
| EP3065705A4 (en) | 2013-11-04 | 2017-10-18 | Board of Regents, The University of Texas System | Compositions and methods for administration of an enzyme to a subject's airway |
| JP6932506B2 (ja) | 2013-11-26 | 2021-09-08 | イエール ユニバーシティ | 細胞透過組成物およびそれを用いる方法 |
| ES2743622T3 (es) | 2013-11-26 | 2020-02-20 | E & B Tech Llc | Tratamiento de la enfermedad autoinmune y/o inflamatoria usando moduladores de la caveolina novedosos |
| JP7496826B2 (ja) | 2018-09-10 | 2024-06-07 | ラング セラピューティクス，エルエルシー | Ｃａｖ－１タンパク質の修飾ペプチドフラグメント及び線維症の治療におけるその使用 |
| CN112996530A (zh) | 2018-09-10 | 2021-06-18 | 得克萨斯州大学系统董事会 | 小窝蛋白-1肽的干粉制剂及其使用方法 |
-
2014
- 2014-03-17 KR KR1020217018508A patent/KR102588702B1/ko active IP Right Grant
- 2014-03-17 CN CN202311699535.8A patent/CN117679487A/zh active Pending
- 2014-03-17 ES ES14762435T patent/ES2875853T3/es active Active
- 2014-03-17 AU AU2014233055A patent/AU2014233055B2/en active Active
- 2014-03-17 WO PCT/US2014/030147 patent/WO2014145389A1/en active Application Filing
- 2014-03-17 DK DK14762435.7T patent/DK2970383T3/da active
- 2014-03-17 JP JP2016503339A patent/JP6603207B2/ja active Active
- 2014-03-17 PT PT147624357T patent/PT2970383T/pt unknown
- 2014-03-17 CN CN201480016012.1A patent/CN105263948B/zh active Active
- 2014-03-17 US US14/775,895 patent/US9630990B2/en active Active
- 2014-03-17 KR KR1020157025554A patent/KR102268883B1/ko active Application Filing
- 2014-03-17 EP EP21168926.0A patent/EP3929207A1/en active Pending
- 2014-03-17 KR KR1020237034239A patent/KR20230148263A/ko active Application Filing
- 2014-03-17 EP EP14762435.7A patent/EP2970383B1/en active Active
- 2014-03-17 CA CA2904870A patent/CA2904870C/en active Active
- 2014-03-17 CN CN201910393777.1A patent/CN110201144B/zh active Active
-
2016
- 2016-06-16 HK HK16106966.9A patent/HK1218924A1/zh unknown
-
2017
- 2017-03-10 US US15/455,670 patent/US10377796B2/en active Active
- 2017-10-09 US US15/727,828 patent/US20180086791A1/en not_active Abandoned
-
2018
- 2018-07-12 AU AU2018205157A patent/AU2018205157A1/en not_active Abandoned
- 2018-07-17 JP JP2018134098A patent/JP6975690B2/ja active Active
-
2019
- 2019-12-03 US US16/702,101 patent/US11161875B2/en active Active
-
2020
- 2020-05-15 AU AU2020203192A patent/AU2020203192A1/en not_active Abandoned
-
2021
- 2021-08-05 JP JP2021128989A patent/JP7378833B2/ja active Active
- 2021-10-12 US US17/499,859 patent/US11780879B2/en active Active
-
2022
- 2022-12-02 US US18/061,084 patent/US20230100467A1/en active Pending
-
2023
- 2023-08-15 US US18/450,056 patent/US20240059736A1/en active Pending
- 2023-10-25 JP JP2023183297A patent/JP2023178440A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2970383T3 (da) | Fremgangsmåde til behandling af fibrose | |
| DK3110988T3 (da) | Metoder til behandling af lithiumholdige materialer | |
| DK3316703T3 (da) | Fremgangsmåde til forbedring af dyrs ydeevne | |
| DK3083540T3 (da) | Fremgangsmåde til fremstilling af substituerede phenoxyphenylketoner | |
| CL2016000098A1 (es) | Método para secado de biomasa | |
| DK2857019T3 (da) | Fremgangsmåde til behandling af multipel sklerose | |
| DK3013544T3 (da) | Fremgangsmåde til betonfremstilling | |
| DK3010352T3 (da) | Fremgangsmåde til fremstilling af fodertilsætning | |
| DK3054782T3 (da) | Fremgangsmåde til tørring af biomasse | |
| DK2956071T3 (da) | Sæt til perifer nerveblokering | |
| BR112015029436A2 (pt) | método de modificação de polímeros | |
| DK3044788T3 (da) | Ikke-uniform parameterkvantificering til avanceret kobling | |
| BR112015019224A2 (pt) | aparelho, e método | |
| BR112015021083A2 (pt) | método | |
| BR112015029076A2 (pt) | método | |
| FI20135921A (fi) | Menetelmä metallien käsittelemiseksi | |
| FR3001642B1 (fr) | Procede de recouvrement de surfaces | |
| EP3026591A4 (en) | FUNCTION DEFINITION METHOD | |
| DK2986325T3 (da) | Fremgangsmåder til behandling af forstyrrelser i urinstofcyklus | |
| DK3016682T3 (da) | Metoder til behandling af kræft | |
| DK3042205T3 (da) | Fremgangsmåde til forbedring af antistofstabilitet | |
| DK2837678T3 (da) | Fremgangsmåde til forbedret afsmeltning | |
| DK3047028T3 (da) | Fermenteringsfremgangsmåde | |
| DK3082860T3 (da) | Fremgangsmåde til behandling af sår | |
| DK3047025T3 (da) | Fremgangsmåde til fremstilling af kappevira |